Clinical Trials Logo
  1. Home
  2. Autoimmune Disease
  3. NCT02948855

Regulation of LncRNA For Breg in Patients With Thymoma and Autoimmune Diseases

Thymoma Clinical Trial

Official title:
Study on Regulation of LncRNA to Regulatory B Cells(Bregs) Through Notch Pathway in Patients With Thymoma and Autoimmune Diseases

Clinical Trial Summary

Initially investigators will find LncRNA which to be able to affect Notch2 signaling pathway; then confirm the relationship between Notch2 and LncRNA, and analysis the regulation mode of LncRNA to Notch2 signaling pathway, and to observe the correlation between LncRNA and thymoma complicated with autoimmune diseases.

Clinical Trial Description

1. This study plans to research the correlation between Bregs and thymoma complicated with autoimmune diseases and the regulation the severity of the disease.

2. Clarify different expression levels of Notch2 signaling pathway in thymoma complicated with autoimmune diseases, and the effect on Regulatory B Cells(Bregs).

3. Find the effective regulation mode of Notch2 signaling pathway and the regulation of Bregs cell development and function in LncRNA. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02948855
Study type Observational
Source Tianjin Medical University Cancer Institute and Hospital
Contact
Status Withdrawn
Phase
Start date October 2016
Completion date May 2018
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT01950572 - Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Terminated NCT00818090 - Paclitaxel and Cisplatin for Thymic Neoplasm Phase 2
Completed NCT00332969 - Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma Phase 2
Completed NCT00921739 - Esophageal Sparing Intensity-modulated Radiation Therapy (IMRT) for Locally-Advanced Thoracic Malignancies Phase 1
Recruiting NCT05255965 - IL-8+ naïve T Cells as a Biomarker for Thymoma Identification
Completed NCT00387868 - Preoperative Treatment of Patients With High Risk Thymoma Phase 2
Completed NCT01272817 - Nonmyeloablative Allogeneic Transplant N/A
Recruiting NCT03466827 - Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma Phase 2
Completed NCT02220855 - A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas Phase 2
Completed NCT03288662 - Relationship Between Computed Tomography Manifestation and Histopathological Classification of Thymic Epithelial Tumors N/A
Active, not recruiting NCT01242072 - Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies Phase 1
Recruiting NCT06029621 - Robot-assisted vs VATS for Thymoma N/A
Active, not recruiting NCT03921671 - Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT) Phase 2
Active, not recruiting NCT01621568 - Sunitinib for Advanced Thymus Cancer Following Earlier Treatment Phase 2
Recruiting NCT05262582 - Comparison of Single Port and Two Ports Robotic Assisted Thoracic Surgery for Thymectomy N/A
Terminated NCT01100944 - A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies Phase 1/Phase 2
Active, not recruiting NCT03968315 - An Investigational Scan (MRI) in Imaging Patients With Newly-Diagnosed or Recurrent Thymoma N/A
Recruiting NCT04162691 - Single Cell Sequencing Analysis of Thymoma
Recruiting NCT06086327 - Application of 68Ga-Pentixafor PET/CT for Thymoma Early Phase 1
Completed NCT01364727 - A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies Phase 2